A Biography lifts the curtain on the private life of Charles Darwin, one of science’s most controversial pioneers.

Heavy Weight Express enables global heavyweight express shipping up to 1,000 kg per piece / 3,000 kg per shipment; Proactive shipment control through dedicated Heavy Weight Priori ...

Scientists revisiting mysterious 540-million-year-old microfossils from Brazil have overturned a major idea about early ...

This year, TIME editors launch the TIME100 Companies: Industry Leaders lists, an expansion of the TIME100 Most Influential Companies issue that dives deeper into 20 sectors to look at the companies ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The U.S. life sciences industry entered 2026 with surprising momentum, following threats of tariffs and disrupted trade, NIH funding cuts, and a sluggish IPO market. Accounting for more than ...

April 16 - OpenAI on Thursday introduced an artificial intelligence model touting increased biology knowledge and scientific research capabilities, as the startup deepens its push into the ‌life ...

SANTA FE, N.M.--(BUSINESS WIRE)--Litmys, a life sciences commercial strategy consulting firm, specializing in the development of commercial readiness analytics, and Konovo, a technology-first ...

One of the world’s leading investment firms has broken its own record with the closing of its $6.3 billion Blackstone Life Sciences VI (BLXS VI) fund, which is 40% larger than its predecessor.

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Blackstone (NYSE: BX) today announced the final close of Blackstone Life Sciences VI (“BXLS VI”). BXLS VI was oversubscribed and closed at its hard cap ...

Blackstone Inc. closed its latest life-sciences fund with $6.3 billion of commitments, the firm’s biggest haul for backing clinical trials of medicines and technologies. The new vehicle, Blackstone ...

Wave Life Sciences (WVE) fell ~57% in the premarket on Thursday as Wall Street reacted to interim data from an early-stage trial for WVE-007, its RNA-based obesity medicine. Citing six-month follow-up ...